1.10
-0.08(-6.78%)
Currency In USD
| Previous Close | 1.18 |
| Open | 1.18 |
| Day High | 1.23 |
| Day Low | 1.1 |
| 52-Week High | 19.51 |
| 52-Week Low | 0.51 |
| Volume | 40,964 |
| Average Volume | 119,403 |
| Market Cap | 37.91M |
| PE | -4.78 |
| EPS | -0.23 |
| Moving Average 50 Days | 1.38 |
| Moving Average 200 Days | 1.15 |
| Change | -0.08 |
If you invested $1000 in Jupiter Neurosciences, Inc. (JUNS) since IPO date, it would be worth $0 as of December 14, 2025 at a share price of $1.1. Whereas If you bought $1000 worth of Jupiter Neurosciences, Inc. (JUNS) shares 1 year ago, it would be worth $200.36 as of December 14, 2025 at a share price of $1.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
GlobeNewswire Inc.
Dec 03, 2025 1:00 PM GMT
Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company
Jupiter Neurosciences to Participate in NobleCon21
Newsfile
Dec 02, 2025 9:15 PM GMT
Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochon
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
GlobeNewswire Inc.
Nov 05, 2025 1:30 PM GMT
Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondri